Industry news that matters to you.  Learn more

Tyme Identifies Potential Method and Biomarker for Converting Malignant Tumors to Inert Calcified Mass

Reading time: 2 minutes

Tyme Technologies, Inc. (Nasdaq: TYME), a biotechnology company using cellular metabolism and oxidative stress to develop cancer therapeutics, today announced it has identified a mechanism and related biomarker that the Company believes could potentiate the calcification of tumors. During clinical evaluation of the Company’s lead product candidate, it was observed that subsequent to SM-88 therapy some lytic bone lesions converted to benign sclerotic bone. Following further examination, the Company believes it has isolated the cause of this conversion and developed a treatment method that can be used in combination with SM-88 to cause calcification of tumors with a particular biomarker. The Company has conducted a small number of tests in canine osteosarcoma and observed positive results, including a rapid ossification of tumors.

“We are excited because this not only supports the potential role of SM-88 in cancer treatment, but could broaden the protection of Tyme’s platform,” stated Tyme CEO, Steve Hoffman. “Given this therapy originated from studying SM-88 treated patients, we hope that the results seen in dogs will have a clear translation back to human subjects.” Previous canine studies have shown no demonstrable side effects from long-term chronic treatment with high doses of Tyme’s proprietary tyrosine derivative.

The calcification of tumors is recognized in several cancer types, including a majority of breast cancers as well as sarcomas and lymphomas. Based on previous independent studies, calcification of a tumor can mitigate its metastatic potential and is associated with favorable survival outcomes. Similar to calcification, we believe that SM-88 has demonstrated an ability to convert some malignant tumors to benign tissue that is metabolically inactive based on positron emission tomography (PET) imaging. This effect was seen in SM-88’s first human study of certain subjects with progressive metastatic disease, where median overall survival was 29 months for patients that achieved “stable disease” under traditional RECIST response criteria. The ability to calcify tumors could lead to increased therapeutic benefit or tumor clearance, building on SM-88’s current effects.

Source: Tyme Technologies